In studies, single-inhaler triple therapy with fluticasone furoate
, umeclidinium, and vilanterol does seem to reduce exacerbations more than LABA/LAMA combination therapy or LABA/inhaled corticosteroid treatment, but that doesn't necessarily mean it should be automatically chosen over dual therapy, the presenter noted.
Triple inhaled therapy for COPD is constituted with an ICS, a LAMA, and a LABA, which is recommended in the GOLD management tactics for COPD patients who have clinically significant symptoms and of high risk of getting frequent or severe exacerbations in spite of treatment with the combination of ICS/LABA or LAMA/LABA. A study showed that consuming the once-daily single-inhaler triple therapy with fluticasone furoate
, umeclidinium, and vilanterol improved a better lung function and HRQoL and a significantly lower rate of moderate or severe COPD exacerbations compared to dual therapy with fluticasone ICS/LABA or LAMA/LABA.
In 5-11-year-old patients with well-controlled asthma, fluticasone furoate/ vilanterol has a similar tolerability, safety profile, pharmacodynamic effect and pharmacokinetic profile as fluticasone furoate
The study randomized patients to 52 weeks of either triple inhaled therapy involving a once-daily combination of 100 mcg fluticasone furoate
(a corticosteroid), 62.5 mcg of the LAMA umeclidinium and 25 mcg of the LABA vilanterol; or dual inhaled therapy involving either 100 mcg fluticasone furoate
plus 25 mcg of vilanterol, or 62.5 mcg of umeclidinium plus 25 mcg of vilanterol.
Fifty-two weeks of a once-daily combination of fluticasone furoate
(an inhaled glucocorticoid), umeclidinium (a long-acting muscarinic antagonist), and vilanterol (a long-acting ?2-agonist) was compared with fluticasone furoate-vilanterol and umeclidinium-vilanterol.
According to a recent study, the CV endpoint in the fluticasone furoate
(FF) (hazard ratio (HR): 0.90; 95% CI: 0.73 to 1.1) groups did not differ from that in the placebo group .
The researchers randomly assigned 61 people with perennial allergic rhinitis to receive either the intranasal steroid fluticasone furoate
(FF) or FF with antioxidants [[beta]-carotene (20 mg/26000 III), ascorbic acid (200 mg), vitamin E (200 mg/200 IU), and selenium (50 [micro]g)] for six weeks.
The Food and Drug Administration last summer approved Flonase Sensimist (fluticasone furoate
, 27.5 meg spray) as a nonprescription treatment for symptoms related to seasonal and perennial allergies.
The closed triple combination therapy comprises three medicines: fluticasone furoate
, an inhaled corticosteroid (ICS), umeclidinium, a long-acting muscarinic antagonist (LAMA) and vilanterol, a long-acting beta2-adrenergic agonist (LABA), delivered once-daily in GSK's Ellipta dry powder inhaler.
Breo Ellipta contains the corticosteroid fluticasone furoate
, as well as vilanterol, a long-acting beta-agonist (LABA).
These are beclomethasone dipropionate (Beclate), budesonide (Rhino-cort, Budeflam), triamcinolone (Nasacor), fluticasone dipropionate (Flixonase, Flo-mist), mometasone (Nasonex) and fluticasone furoate
A newer intranasal corticosteroid has been recently introduced, Fluticasone furoate
(Veramyst) is thought to have more affinity for the corticosteroid receptor.